henatinib   Click here for help

GtoPdb Ligand ID: 9930

Synonyms: compound 25 [PMID: 21028894]
Compound class: Synthetic organic
Comment: Henatinib is a kinase inhibitor with some selectivity for VEGFR2 (KDR). Discovery was reported by Cho et al. (2010), the same article that disclosed famitinib [1]. The name henatinib is linked to the structure of 'compound 25' in the article by Gu et al. (2010) that describes a method for detecting and quantifying henatinib maleate in rat plasma [2].
Henatinib is a 'pseudo' INN, that takes the form of an INN for a kinase inhibitor, but has not been submitted to the World Health Organisation for ratification.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 7
Hydrogen bond donors 3
Rotatable bonds 5
Topological polar surface area 97.9
Molecular weight 468.22
XLogP 1.03
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES OC(CN1CCCc2c(C1=O)c(C)c([nH]2)C=C1C(=O)Nc2c1cc(F)cc2)CN1CCOCC1
Isomeric SMILES O[C@@H](CN1CCCc2c(C1=O)c(C)c([nH]2)/C=C/1\C(=O)Nc2c1cc(F)cc2)CN1CCOCC1
InChI InChI=1S/C25H29FN4O4/c1-15-22(12-19-18-11-16(26)4-5-20(18)28-24(19)32)27-21-3-2-6-30(25(33)23(15)21)14-17(31)13-29-7-9-34-10-8-29/h4-5,11-12,17,27,31H,2-3,6-10,13-14H2,1H3,(H,28,32)/b19-12-/t17-/m1/s1
No information available.
Summary of Clinical Use Click here for help
A Phase 1 clinical study of henatinib in patients with advanced solid tumours (NCT01416623) was terminated. The reasons for discontinuing the trial are undisclosed.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT01416623 A Phase I Study of Henatinib in Patients With Advanced Solid Malignancies Phase 1 Interventional Jiangsu HengRui Medicine Co., Ltd.